NOVARTIS AGNVS

時価総額

PER

	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
Revenue from sale of goods	51,900	47,498	48,659	51	50	45
Other revenue	1,266	1,179	1,239	1	1	1
Gross profit from continuing operations	34,759	34,252	34,777	37	36	34
Selling, general and administration	16,471	14,369	14,197	14	14	12
Cost of goods sold	18,407	14,425	15,121	15	15	12
Research and development	9,074	9,402	8,980	9	9	11
Other income	1,690	2,031	1,742	1	805	1
Other expense	2,735	3,426	3,190	2	3	2
Operating income from continuing operations	8,169	9,086	10,152	11	9	9
(Loss)/income from associated companies	6,438	659	673	15	-9	-13
Other financial income and expense	185	45	-78	-80	20	222
Interest expense	957	850	869	811	837	855
Income before taxes from continuing operations	13,835	8,940	9,878	26	8	9
Income taxes	1,221	1,793	1,807	2	1	551
Net income from continuing operations	-	7,147	8,071	24	-	8
Gain on distribution of Sandoz Group AG to Novartis AG shareholders	-	4,691	-	-	-	5
Net loss from discontinued operations before gain on distribution	-	-101	-	-	-	422
Net income from discontinued operations	-	4,590	-	-	-	6
Net income	12,614	11,737	8,071	24	6	14
Shareholders of Novartis AG	12,611	11,732	8,072	24	6	14
Non-controlling interests	3	5	-1	-3	-	4
Continuing operations	-	3.12	3.55	10.71	-	4.13
Discontinued operations	-	2	-	-	-	3.02
Basic earnings per share	5.44	5.12	3.55	10.71	3.19	7.15
Diluted earnings per share	5.38	5.06	3.52	10.63	3.17	7.1
Continuing operations	-	3.08	3.52	10.63	-	4.1
Discontinued operations	-	1.98	-	-	-	3
Diluted earnings per share	5.38	5.06	3.52	10.63	3.17	7.1